Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 26/01/2012
PIL Tasigna 200 mg hard capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 26/01/2012 and displayed until Current
Reasons for adding or updating:
  • Change to Further Information section
Updated on 09/01/2012 and displayed until 26/01/2012
Reasons for adding or updating:
  • Change to side-effects
Updated on 15/07/2011 and displayed until 09/01/2012
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 10/06/2011 and displayed until 15/07/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to side-effects
  • Change to MA holder contact details
Updated on 10/01/2011 and displayed until 10/06/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
Updated on 27/09/2010 and displayed until 10/01/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 16/02/2010 and displayed until 27/09/2010
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 16/09/2009 and displayed until 16/02/2010
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to drug interactions
Updated on 24/08/2009 and displayed until 16/09/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 16/05/2008 and displayed until 24/08/2009
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  nilotinib hydrochloride monohydrate